Literature DB >> 29748197

Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial Fibrillation.

Jose R Garcia1, Peter F Campbell2, Gautam Kumar3,4, Jonathan J Langberg3, Liliana Cesar5, Juline N Deppen6,3, Eric Y Shin3, Neal K Bhatia3, Lanfang Wang3, Kai Xu3, Frank Schneider3,7, Brian Robinson7, Andrés J García1, Rebecca D Levit8.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although treatment options for AF exist, many patients cannot be maintained in normal sinus rhythm. Amiodarone is an effective medication for AF but has limited clinical utility because of off-target tissue toxicity.
METHODS: Here, we use a pig model of AF to test the efficacy of an amiodarone-containing polyethylene glycol-based hydrogel. The gel is placed directly on the atrial epicardium through the pericardial space in a minimally invasive procedure using a specially designed catheter.
RESULTS: Implantation of amiodarone-containing gel significantly reduced the duration of sustained AF at 21 and 28 days; inducibility of AF was reduced 14 and 21 days post-delivery. Off-target organ drug levels in the liver, lungs, thyroid, and fat were significantly reduced in animals treated with epicardial amiodarone gel compared with systemic controls in small-animal distribution studies.
CONCLUSIONS: The pericardium is an underutilized therapeutic site and may be a new treatment strategy for AF and other cardiovascular diseases.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  amiodarone; arrhythmias, cardiac; atrial fibrillation; hydrogel, polyethylene glycol; pericardium

Mesh:

Substances:

Year:  2018        PMID: 29748197      PMCID: PMC5951400          DOI: 10.1161/CIRCEP.118.006408

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  49 in total

Review 1.  Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy.

Authors:  Frits W Prinzen; Kevin Vernooy; Angelo Auricchio
Journal:  Circulation       Date:  2013-11-26       Impact factor: 29.690

2.  Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization.

Authors:  Edward A Phelps; Kellie L Templeman; Peter M Thulé; Andrés J García
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

3.  Trends in the outpatient treatment of atrial fibrillation in the USA from 2001 to 2010.

Authors:  Amarsinh M Desai; Teresa M Cavanaugh; Vibha C A Desai; Pamela C Heaton; Christina M L Kelton
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-03-12       Impact factor: 2.890

4.  Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure.

Authors:  R Candinas; J Frielingsdorf; H R Ha; T Carrel; M Turina; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1998-01       Impact factor: 2.953

5.  Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.

Authors:  Kaori Shinagawa; Akiko Shiroshita-Takeshita; Gernot Schram; Stanley Nattel
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

6.  Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy.

Authors:  Roland Richard Tilz; Andreas Rillig; Anna-Maria Thum; Anita Arya; Peter Wohlmuth; Andreas Metzner; Shibu Mathew; Yasuhiro Yoshiga; Erik Wissner; Karl-Heinz Kuck; Feifan Ouyang
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

7.  Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study.

Authors:  Vincent E Hagens; Adelita V Ranchor; Eric Van Sonderen; Hans A Bosker; Otto Kamp; Jan G P Tijssen; J Herre Kingma; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  J Am Coll Cardiol       Date:  2004-01-21       Impact factor: 24.094

8.  Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs.

Authors:  András Vereckei; J Cristopher Gorski; Michael Ujhelyi; Rahul Mehra; Douglas P Zipes
Journal:  Cardiovasc Drugs Ther       Date:  2004-07       Impact factor: 3.727

9.  One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure.

Authors:  Douglas L Mann; Randall J Lee; Andrew J S Coats; Gheorghe Neagoe; Dinu Dragomir; Enrico Pusineri; Massimo Piredda; Luca Bettari; Bridget-Anne Kirwan; Robert Dowling; Maurizio Volterrani; Scott D Solomon; Hani N Sabbah; Andy Hinson; Stefan D Anker
Journal:  Eur J Heart Fail       Date:  2015-11-11       Impact factor: 15.534

10.  Cellular encapsulation enhances cardiac repair.

Authors:  Rebecca D Levit; Natalia Landázuri; Edward A Phelps; Milton E Brown; Andres J García; Michael E Davis; Giji Joseph; Robert Long; Susan A Safley; Jonathan D Suever; Alicia N Lyle; Collin J Weber; W Robert Taylor
Journal:  J Am Heart Assoc       Date:  2013-10-10       Impact factor: 5.501

View more
  2 in total

1.  A Hydrogel Strategy to Augment Tissue Adenosine to Improve Hindlimb Perfusion.

Authors:  Michael N Sayegh; Kimberly A Cooney; Woojin M Han; Lanfang Wang; Frederick Strobel; Laura M Hansen; Andrés J García; Rebecca D Levit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-22       Impact factor: 10.514

2.  Therapeutic payload delivery to the myocardium: Evolving strategies and obstacles.

Authors:  Tarek Shazly; Arianna Smith; Mark J Uline; Francis G Spinale
Journal:  JTCVS Open       Date:  2022-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.